TommyTP schreef op 14 september 2018 12:55:
Based on our NPV based valuation, we believe that Pharming is still substantially undervalued at the current share price of EUR 1.38. We have increased our valuation for the company and estimate that the company’s current total value should increase
from EUR 1.1 billion to EUR 1,6 million, which translates, based on an expected number of issued shares of approximately 657 million, into EUR 2.40 per share. At this moment, we do not address value to other programs in Pharming’s pipeline. This conservative approach offers potential upside for the share price.
Van Leeuwenhoek. Blijft een interessante quote. Als er straks na het FDA besluit (indien positief) een paar wakker worden kan het hard gaan.....